Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
The recent advent of robust methods to grow human tissues as 3D organoids allows us to recapitulate the 3D architecture of tumors in an in vitro setting and offers a new orthogonal approach for drug discovery. However, organoid culturing with extracellular matrix to support 3D architecture has been challenging for high-throughput screening (HTS)-based drug discovery due to technical difficulties. Using genetically engineered human colon organoids as a model system, here we report our effort to miniaturize such 3D organoid culture with extracellular matrix support in high-density plates to enable HTS. We first established organoid culturing in a 384-well plate format and validated its application in a cell viability HTS assay by screening a 2036-compound library. We further miniaturized the 3D organoid culturing in a 1536-well ultra-HTS format and demonstrated its robust performance for large-scale primary compound screening. Our miniaturized organoid culturing method may be adapted to other types of organoids. By leveraging the power of 3D organoid culture in a high-density plate format, we provide a physiologically relevant screening platform to model tumors to accelerate organoid-based research and drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The size of these organ-like structures ranges from 100 µm (lung organoid) to 2 mm (brain organoid) and they can be cultivated in small dimensions (for example, 96-well or 384-well plates25,26), thereby being suitable for high-throughput screening.”
From Human disease models in drug development (2023) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 2×
“0 indicates that the assay is robust for HTS (Zhang et al., 1999).”
BackgroundModeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Attempts to develop targeted therapies for this genomic subset of patients have been largely unsuccessful, although therapeutic targeting of KRAS tumors has now advanced to phase II clinical trials, offering much hope for patients (Canon et al., 2019).”
BackgroundPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 3×
“Compared to the traditional 2D culture using transformed cell lines, primary organoids have the advantage of retaining the characteristics of the cancer cells from the original patient’s tissue, including their differentiated morphology and response to drugs (Clevers, 2016; Weeber et al., 2017; Abbasi, 2018; Sachs et…”
BackgroundA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · cited 8×
“Currently, only small scales, e.g. <100 compounds, have been tested as proof-of-concept to exam the response of 3D organoids in ECM to drugs (Gao et al., 2014; van de Wetering et al., 2015; Schutte et al., 2017; Sachs et al., 2018; Li et al., 2019).”
BackgroundMethodResultInfluentialDrost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“They represent near-physiological models for use in both basic and translational research (Drost and Clevers, 2018; Yang et al., 2018; Castellon, 2019; Kim et al., 2019).”
MethodOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Three-dimensional cell culture: the missing link in drug discovery
Breslin, S., & O’Driscoll, L. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.003 · Cited by 1,332 · cited 1×
“Due to technical simplicity and ease of handling, traditionally cell growth and proliferation assays in 2D adherent cell monolayers on plastic surfaces have been widely used in the HTS field for the discovery of new cancer drugs (Breslin and O’Driscoll, 2013).”
MethodA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche
Ootani, A., Li, X., Sangiorgi, E., Ho, Q. T., Ueno, H., Toda, S., Sugihara, H., Fujimoto, K., Weissman, I. L., Capecchi, M. R., et al. (2009) · Nature Medicine · doi:10.1038/nm.1951 · Cited by 906 · cited 2×
“Recovery of organoids from frozen stock Human colon KRAS organoids were generated by engineering normal colon tissue organoids and characterized as previously described (Ootani et al., 2009).”
MethodSelf-citationPatient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812 · cited 2×
“They represent near-physiological models for use in both basic and translational research (Drost and Clevers, 2018; Yang et al., 2018; Castellon, 2019; Kim et al., 2019).”
BackgroundMethodWeaver, V. M., Lelièvre, S., Lakins, J. N., Chrenek, M. A., Jones, J. C. R., Giancotti, F., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 793
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.010 · Cited by 755
Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis
Huch, M., Bonfanti, P., Boj, S. F., Sato, T., Loomans, C. J. M., van de Wetering, M., Sojoodi, M., Li, V. S. W., Schuijers, J., Gracanin, A., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.204 · Cited by 711
High-throughput screening assays for the identification of chemical probes
Inglese, J., Johnson, R. L., Simeonov, A., Xia, M., Zheng, W., Austin, C. P., & Auld, D. S. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.17 · Cited by 614
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Skardal, A., Shupe, T., & Atala, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.003 · Cited by 512 · cited 1×
“Cell culturing in 2D does not account for the extracellular microenvironment, cell–cell interactions, and cell–matrix interactions normally found in tissues (Skardal et al., 2016).”
BackgroundTumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
Weeber, F., Ooft, S. N., Dijkstra, K. K., & Voest, E. E. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.012 · Cited by 486
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture
Li, X., Nadauld, L., Ootani, A., Corney, D. C., Pai, R. K., Gevaert, O., Cantrell, M. A., Rack, P. G., Neal, J. T., Chan, C. W.-M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3585 · Cited by 442
Self-citationCrespo, M., Vilar, E., Tsai, S.-Y., Chang, K., Amin, S., Srinivasan, T., Zhang, T., Pipalia, N. H., Chen, H. J., Witherspoon, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4355 · Cited by 399 · cited 1×
“Consistent with our selection, BME has been used successfully for supporting many tissues or tumor-derived organoid culture as a 3D scaffold (Crespo et al., 2017; Sachs et al., 2018; Suzuki et al., 2018).”
MethodSchütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Education reforms struggle against apartheid's legacy
(1996) · Nature · doi:10.1038/384014a0 · Cited by 291
High throughput screening in drug discovery
Carnero, A. (2006) · Clinical and Translational Oncology · doi:10.1007/s12094-006-0048-2 · Cited by 289
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
Verissimo, C. S., Overmeer, R. M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B. V., van der Ven, M., Wetering, M. V. D., Egan, D. A., et al. (2016) · eLife · doi:10.7554/elife.18489 · Cited by 263
Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma
Saito, Y., Muramatsu, T., Kanai, Y., Ojima, H., Sukeda, A., Hiraoka, N., Arai, E., Sugiyama, Y., Matsuzaki, J., Uchida, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.088 · Cited by 230
Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity
Li, L., Knutsdottir, H., Hui, K., Weiss, M. J., He, J., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.121490 · Cited by 215
Weaver, V. M., Lelièvre, S. A., Lakins, J. N., Chrenek, M. A., Jones, J., Giancotti, F. G., Werb, Z., & Bissell, M. J. (2002) · University of North Texas Digital Library (University of North Texas) · doi:10.1016/s1535-6108%2802%2900125-3 · Cited by 208
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Castellano, E., Sheridan, C., Thin, M. Z., Nye, E., Spencer-Dene, B., Diefenbacher, M. E., Moore, C., Kumar, M. S., Murillo, M. M., Grönroos, E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.012 · Cited by 182
Steckel, M., Molina-Arcas, M., Weigelt, B., Marani, M., Warne, P. H., Kuznetsov, H., Kelly, G., Saunders, B., Howell, M., Downward, J., et al. (2012) · Cell Research · doi:10.1038/cr.2012.82 · Cited by 171
Hou, S., Tiriac, H., Sridharan, B. P., Scampavia, L., Madoux, F., Seldin, J., Souza, G. R., Watson, D., Tuveson, D., & Spicer, T. P. (2018) · SLAS Discovery · doi:10.1177/2472555218766842 · Cited by 169
Boehnke, K., Iversen, P. W., Schumacher, D., Lallena, M. J., Haro, R., Amat, J., Haybaeck, J., Liebs, S., Lange, M., Schäfer, R., et al. (2016) · SLAS Discovery · doi:10.1177/1087057116650965 · Cited by 144
Monitoring the progression of cell death and the disassembly of dying cells by flow cytometry
Jiang, L., Tixeira, R., Caruso, S., Atkin‐Smith, G. K., Baxter, A. A., Paone, S., Hulett, M. D., & Poon, I. K. H. (2016) · Nature Protocols · doi:10.1038/nprot.2016.028 · Cited by 132
Patient-derived organoids: a promising model for personalized cancer treatment
Yang, H., Sun, L., Liu, M., & Mao, Y. (2018) · Gastroenterology Report · doi:10.1093/gastro/goy040 · Cited by 96
Suzuki, K., Murano, T., Shimizu, H., Ito, G., Nakata, T., Fujii, S., Ishibashi, F., Kawamoto, A., Anzai, S., Kuno, R., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1437-3 · Cited by 83
A 1536-Well 3D Viability Assay to Assess the Cytotoxic Effect of Drugs on Spheroids
Madoux, F., Tanner, A., Vessels, M., Willetts, L., Hou, S., Scampavia, L., & Spicer, T. P. (2017) · SLAS Discovery · doi:10.1177/2472555216686308 · Cited by 72
Assessment of Cell Viability with Single-, Dual-, and Multi-Staining Methods Using Image Cytometry
Chan, L. L., McCulley, K. J., & Kessel, S. L. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6960-9_3 · Cited by 63
High Throughput Screening for Drug Discovery: Continually Transitioning into New Technology
Fox, S., Farr-Jones, S., & Yund, M. A. (1999) · SLAS Discovery · doi:10.1177/108705719900400405 · Cited by 59
Zhu, J.-W., Nagasawa, H., Nagura, F., Mohamad, S. B., Uto, Y., Ohkura, K., & Hori, H. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00297-7 · Cited by 55
Mo, X., Tang, C., Niu, Q., Ma, T., Du, Y., & Fu, H. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.011 · Cited by 54
Self-citationKatano, T., Ootani, A., Mizoshita, T., Tanida, S., Tsukamoto, H., Ozeki, K., Ebi, M., Mori, Y., Kataoka, H., Kamiya, T., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.051 · Cited by 49
High-Throughput Screening for Drug Discovery
(2022) · IntechOpen eBooks · doi:10.5772/intechopen.91075 · Cited by 45
PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
Drilon, A., Schoenfeld, A. J., Arbour, K. C., Litvak, A., Ni, A., Montecalvo, J., Yu, H. A., Panora, E., Ahn, L., Kennedy, M., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003665 · Cited by 31 · cited 1×
“Our results support the recent clinical trial of bortezomib in nonsmall cell lung cancer with two exceptional responders, both of whom had KRAS mutant tumors (Drilon et al., 2019).”
ResultSurvivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas
Sumi, T., Hirai, S., Yamaguchi, M., Tanaka, Y., Tada, M., Yamada, G., Hasegawa, T., Miyagi, Y., Niki, T., Watanabe, A., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4365 · Cited by 20
Patient-Derived Organoids Predict Cancer Treatment Response
Abbasi, J. (2018) · JAMA · doi:10.1001/jama.2018.3760 · Cited by 15
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Griner, L. A. M., Gampa, K., Do, T., Nguyen, H. T. L., FARLEY, D. L., Hogan, C. J., Auld, D. S., & Silver, S. J. (2018) · Journal of Visualized Experiments · doi:10.3791/57476 · Cited by 12
Using Heart Pump Data to Manage Cardiogenic Shock
Abbasi, J. (2018) · JAMA · doi:10.1001/jama.2018.3646 · Cited by 11
Johns, M. A., Meyerkord, C. L., Du, Y., & Fu, H. (2014) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207317666140109125415 · Cited by 5
Self-citationPatient‐derived organoids: New co‐clinical model to predict treatment response in cancer?
Castellón, E. A. (2018) · Oral Diseases · doi:10.1111/odi.12988 · Cited by 5
Cited by
Human disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Wensink, G. E., Elias, S. G., Mullenders, J., Koopman, M., Boj, S. F., Kranenburg, O. W., & Roodhart, J. M. L. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00168-1 · Cited by 323
Applications of organoids for cancer biology and precision medicine
Lo, Y.-H., Karlsson, K., & Kuo, C. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0102-y · Cited by 182
Self-citationAdvances in artificial intelligence for drug delivery and development: A comprehensive review
Gholap, A. D., Uddin, M. J., Faiyazuddin, M., Omri, A., Gowri, S., & Khalid, M. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108702 · Cited by 179
3D cell cultures toward quantitative high-throughput drug screening
Wang, Y., & Jeon, H. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.014 · Cited by 157
Metadata
- Authors
- Du, Y., Li, X., Niu, Q., Mo, X., Qui, M., Ma, T., Kuo, C. J., & Fu, H.
- Affiliations
- Emory University (US)
- Stanford Medicine (US)
- Corresponding author
- Du, Yuhong
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-17
- Volume
- 12
- Issue
- 8
- Pages
- 630-643
- ISSN
- 1674-2788 (ISSN-L)
- 1759-4685
- PMC
- PMC7751183
- OpenAlex
- W3042505563
- Cited by
- 125
- References
- 53
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 24 · 2023: 23 · 2022: 18 · 2021: 13 · 2020: 2
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Molecular Cell Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- NCI Cancer Target Discovery and Development (1U01CA217875, 1U01CA217851)
- RAS Synthetic Lethal Network (1U01CA199241)
- Emory Lung Cancer SPORE
- NIH (P50CA217691, UL1-TR002378)
- Winship Cancer Institute (NIH 5P30CA138292)
- Emory WHSC 10X Single Cell Sequencing Seed Grant
- Emory Woodruff Health Sciences Center Synergy Award
- Imagine, Innovate and Impact
- Funds from the Emory School of Medicine
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Zebrafish Biomedical Research Applications
- Keywords
- 3D organoids, colon organoids, high-throughput screening, ultra-high-throughput screening, 1536-well plates, 384-well plate, extracellular matrix, drug discovery, compound screening, tumor models
- MeSH terms
- Colon, Humans, Miniaturization, Organoids, Cryopreservation, Cell Culture Techniques, Imaging, Three-Dimensional, Cell Shape, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.